EUCTR2013-000054-22-GB进行中（未招募）1 期
OPEN-LABEL, PHASE IIIB STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS TOCILIZUMAB (MONOTHERAPY OR COMBINATION THERAPY WITH METHOTREXATE OR OTHER DMARDS) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE AN INADEQUATE RESPONSE TO CURRENT NON-BIOLOGIC DMARD THERAPY OR THE FIRST ANTI-TNF BIOLOGIC AGENT - ACT-MOVE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet the following criteria for study entry:
- •1. Able and willing to give written informed consent and comply with the requirements of the study protocol.
- •2. Patients at least 18 years of age.
- •3. Patients with a diagnosis of active RA according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria.
- •4. Oral corticosteroids (=10 mg/day prednisone or equivalent) and nonsteroidal anti- inflammatory drugs (NSAIDs; up to the maximum recommended dose) are permitted if on a stable dose regimen for =4 weeks prior to Baseline.
- •5. Permitted non-biologic DMARDs are allowed if at a stable dose for at least 4 weeks prior to Baseline.
- •6. Receiving treatment on an outpatient basis, not including Tocilizumab.
- •7. Females of childbearing potential and males with female partners of childbearing potential may participate in this study only if using a reliable means of contraception (e.g., physical barrier [patient or partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device) during the study. Females of childbearing potential and males with female partners of childbearing potential must use a reliable means of contraception for at least 3 months following the last dose of TCZ.
- •8. If female of childbearing potential, the patient must have a negative pregnancy test at Screening and Baseline visits.
- •9.Patients who have an inadequate response to current non-biologic DMARD therapy or the first anti-TNF agent (in monotherapy or in combination with MTX or other non-biologic DMARDs). Inadequate response to anti-TNF treatment is defined as not achieving an adequate response to treatment at 24 weeks or after a minimum period of 12 weeks therapy if permitted by local guidance (timing of assessment according to local clinical practice and no more than 8 weeks post-Week 24) defined by NICE as a DAS28 score improvement of less than 1.2 or patients achieving a 1.2 reduction in DAS28 but not achieving low disease activity (current DAS28 ESR above 3.2) and have not been previously exposed to treatment with tocilizumab.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A patient will be excluded if the answer to any of the following statements is yes”.
- •1. Major surgery (including joint surgery) within 8 weeks prior to Screening or planned major surgery within 6 months following baseline.
- •2. Rheumatic autoimmune disease other than RA, including systemic lupus erythematosis, mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty’s syndrome). Secondary Sjögren’s syndrome with RA is permitted.
- •3. Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis (Appendix 2).
- •4. Diagnosis of juvenile idiopathic arthritis or juvenile RA, and/or RA before the age of 16.
- •5. Prior history of or current inflammatory joint disease other than RA (e.g., gout, Lyme disease, seronegative spondyloarthropathy including reactive arthritis, psoriatic arthritis, and arthropathy of inflammatory bowel disease).
- •Excluded Previous or Concomitant Therapy:
- •6. Exposure to Tocilizumab (either IV or SC) at any time prior to Baseline.
- •7. Treatment with any investigational agent within 4 weeks (or five half-lives of the investigational drug, whichever is longer) of Screening.
- •8. Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, some examples are CAMPATH, anti CD4, anti-CD5, anti CD3, anti CD19, and anti CD20.
- •9. Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline.
- •10. Intraarticular (IA) or parenteral corticosteroids within 4 weeks prior to Baseline.
- •11. Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline.
- •12. Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation.
- •Exclusions for General Safety:
- •13. History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies.
- •14. Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus), or GI disease.
- •15. History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower GI disease such as Crohn’s disease, ulcerative colitis, or other symptomatic lower GI conditions that might predispose to perforation.
- •16. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis [TB] and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds).
- •17. Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening.
- •18. Active TB requiring treatment within the previous 3 years. Patients should be screened for latent TB and, if positive, treated following local practice guidelines prior to initiating Tocilizumab. However, if local practice or guidelines allow reference to test results that were obtained prior to the screening period as part of routine clinical practice, this is allowed. Patients treated for TB with no recurrence in 3 years are permitted.
- •19. Current liver disease as determined by the investigator.
- •20. Positive hepatitis B surface antigen (HbsAg) or hepatitis C antibody.
- •21. Primary or secondary immunodef
研究者
相似试验
进行中（未招募）
1 期
EVALUATION OF EFFICACY AND SAFETY OF STANDARD CHEMOTHERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS OF 55 YEARS AND OLDER WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA.EUCTR2010-022855-46-DEDekan des Fachbereichs Medizin der Goethe Universität, represented by the Coordinating Investigator75
进行中（未招募）
不适用
AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+ OR BCR-ABL+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).EWALL-PH-01 - EWAPhiladelphia chromosome positive Acute Lymphoblastic LeukemiaEUCTR2006-005694-21-DECH-Versailles55
进行中（未招募）
1 期
AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+ OR BCR-ABL+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).EWALL-PH-01 - EWAPhiladelphia chromosome positive Acute Lymphoblastic LeukemiaEUCTR2006-005694-21-FRCH-Versailles55
进行中（未招募）
1 期
EVALUATION OF EFFICACY AND SAFETY OF STANDARD CHEMOTHERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS OF 55 YEARS AND OLDER WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA.Philadelphia chromosome positive Acute Lymphoblastic Leukemia in elderly Patients (55 years and older)MedDRA version: 17.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864EUCTR2010-022855-46-ESFundación PETHEMA79
招募中
不适用
AN OPEN LABEL PHASE 2A STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF (+)-SJ000557733 (SJ733), WITH OR WITHOUT COMBINATION WITH COBICISTAT, IN ADULT PATIENTS WITH ACUTE, UNCOMPLICATED PLASMODIUM FALCIPARUM OR VIVAX MALARIA MONO-INFECTION OVER A 42 DAY PERIOD-B50 Plasmodium falciparum malaria-B51 Plasmodium vivax malariaPlasmodium falciparum malariaPlasmodium vivax malariaB50B51PER-045-20Rodney Kiplin Guy,23